

Supplementary Information

Article title: Re-evaluating the Neutropenia–Survival Paradigm in Irinotecan-based Therapy for Advanced Gastric Cancer: Post-Hoc Analysis of the RINDBeRG Trial

Supplementary Table 1 Baseline characteristics according to baseline absolute neutrophil counts

Factors	IRI + RAM		IRI	
	Low ANC N = 55	High ANC N = 44	Low ANC N = 42	High ANC N = 54
Age, median (range)	67 (46–80)	67 (40–87)	65.5 (36–78)	67 (40–80)
Sex, male, %	80.0	72.7	78.6	87.0
ECOG PS 0, %	67.3	40.9	50.0	42.6
No. of metastatic sites, median (range)	2 (1–5)	2 (1–5)	2 (1–3)	2 (1–5)
Prior gastrectomy, %	58.2	38.6	73.8	37.0
ALP, median (range)	111 (43–305)	118 (0–1458)	89 (18–591)	124 (43–828)
Liver metastasis, %	45.5	43.2	31.0	57.4
Peritoneal metastasis, %	32.7	40.9	50.0	25.9
Prior nivolumab, %	58.2	43.2	47.6	25.9
Modified GPS 0/1/2, %	58.2/27.3/14.5	16.3/51.2/32.6	56.1/34.1/9.8	24.1/44.4/31.5
Histology, diffuse, %	47.3	40.9	42.9	44.4
Histology, intestinal, %	49.1	47.7	50.0	53.7
Histology, other, %	3.6	11.4	7.1	1.9
HER2 positive, %	14.5	18.2	14.3	16.7

ANC, absolute neutrophil count; IRI, irinotecan; RAM, ramucirumab; ECOG PS, Eastern Cooperative Oncology Group performance status; ALP, alkaline phosphatase; GPS, Glasgow Prognostic Score; HER2, human epidermal growth factor receptor 2.